FDA 510(k) & ISO Certified

Preventing the Preventable.

Electrical Stimulation Pressure Injury Prevention Platform

NeuroKinetic Medical stops Stage I & II pressure injuries before they progress — using proprietary electrical stimulation proven in 412-patient RCT trials across hospital, SNF, and home settings.

Platform outcomes — prospective RCT (n=412)
87%
Reduction in hospital-acquired pressure injuries in pilot cohort
4.1×
ROI for health systems — cost savings vs. treatment spend
Electrical Stimulation Staff-Independent Razor/Blade Revenue
FDA 510(k) ISO Certified Health Canada ✓ CE Mark Q2 2027
Platform
Explore NeuroKinetic Medical

Navigate to any section to learn more about who we are, why this moment matters, what Prelivia does, and how it's proven.

🎯
About Us
Who we are, our mission, and the $26B problem we’re solving.
⚡
Why Now
Four forces that make NeuroKinetic possible and necessary today.
📄
Platform Features
Electrical stimulation platform — how it works, what it prevents, and the business model.
📈
Clinical Background
87% HAPI reduction. 412-patient RCT. 5 peer-reviewed publications.
🏆
Our Differentiators
Why no one does what we do — IP moat, FDA clearance, outcomes pricing.
👥
Team
Founders with clinical depth, commercial execution, and technology leadership.
🤝
Partners
Cleveland Clinic, Atrium Health, Medtronic, Philips, and more.
📰
News
Clinical insights and perspectives from the NeuroKinetic Medical team.

Ready to learn more?

Whether you’re a clinician, health system leader, or investor — we’d like to talk.

Get in touch
About Us

The only AI-powered clinical intelligence platform for pressure injury prevention and management.

Founded on 15+ years of electrical stimulation science, cleared by the FDA and Health Canada, and now executing on US commercial launch.

"Preventing the Preventable. Powered by Proven Science."

NeuroKinetic Medical is a medtech company transforming outcomes for patients at risk of pressure injuries — a costly, largely preventable clinical burden affecting millions of patients annually across hospital, long-term care, and home health settings.

Our flagship platform, Prelivia™, targets Stage I and Stage II pressure wounds — the 98.7% of pressure injuries that are still reversible — before they progress to the costly, unreimbursed Stage III and IV events that devastate patients and health system finances alike.

Built on 15+ years of electrical stimulation IP through our acquisition of Rehabtronics Inc., and cleared by the FDA and Health Canada, we are now executing on US commercial launch while advancing the next generation of the platform.

$26B
Annual US pressure injury economic burden
3M+
Americans treated for pressure wounds annually
60K+
Deaths per year attributed to pressure wounds
$125K
Average cost per Stage IV pressure ulcer

Want to know more?

Explore our clinical evidence, platform features, or reach out directly.

Contact Us
Why Now

The convergence moment has arrived

Four forces have aligned to make NeuroKinetic not just possible, but necessary — today.

01

Physical AI maturity

Edge technology and AI inference is now part of hospital and SNF infrastructure — creating the connected, sensor-enabled environment that NeuroKinetic leverages for monitoring and intervention.

02

CMS penalty regime

CMS penalties and litigation costs now make pressure injuries a P&L line item. New regulations extend penalties to Stage II injuries. The average nursing home pressure ulcer lawsuit pays out $500K+.

$3M+ annual revenue at risk per hospital
03

Growing risk population & cost

Adults 65+ will exceed 20% of the US population by 2030. ICU admissions, post-surgical patients, and SNF long-stay residents are all rising, making prevention one of the highest-yield interventions available.

04

Staffing crisis

Nurse-to-patient ratios are at historic lows — frontline automation of intervention and monitoring is no longer optional. With Prelivia, the same preventive outcome requires approximately 10 minutes of nursing time per patient per session.

2+ hours → ~10 min nursing time per patient

See how Prelivia addresses these forces

Platform features built to solve every one of these problems directly.

Platform Features

Prelivia™ — what sets it apart

A bedside durable unit plus proprietary single-use consumable pads — FDA 510(k) cleared and deployable in hospital, long-term care, and home settings with minimal nursing burden.

Prelivia targets the 98.7% of pressure injuries that are still reversible — before they advance to Stage III and IV. It works in every setting, with every patient population, with 100% patient acceptance in all clinical trials.

ModalityElectrical stimulation (ES)
Tissue oxygenation ↑+28% (spO₂)
Tissue injury reduction80% less
Nursing time / patient~10 minutes
Patient acceptance100% in all trials
Revenue modelRazor / Razor Blade
IP8 patents issued, 2 pending
SettingsHospital · LTC · Home

Preventive intervention

Stops Stage I & II pressure wounds from progressing to costly, unreimbursed Stage III & IV events. Intervenes before visible breakdown — the 98.7% window where injuries are still reversible.

Coverage where it counts

Addresses the sacrum and buttocks — 59% of all pressure wound sites. Electrical stimulation restores blood flow and oxygenation to at-risk tissue, preventing ischemic injury before it forms.

Staff-independent efficacy

Electrical stimulation works regardless of staffing ratios or nurse compliance. ~10 minutes of nursing time per patient vs. 2+ hours for traditional turning protocols.

Home & facility ready

Portable and designed for ease-of-use across hospital, long-term care, remote, and home healthcare settings. 250 nurses trained to date — with 100% patient acceptance in all clinical trials.

Expandable platform

Roadmap includes comprehensive wound and venous ulcer management — significantly expanding the addressable market beyond pressure injuries.

Proven science

8 patents issued, 2 pending. 5 peer-reviewed publications. 80% less tissue injury in pre-clinical and clinical studies. 28% increase in tissue oxygenation (spO₂).

Request a Prelivia demo

Our clinical team will walk you through the platform, share outcomes data for your patient population, and support your evaluation process.

Request a demo
Clinical Background

De-risked: clinical, regulatory & market milestones achieved

A rigorous, peer-reviewed evidence base supporting the safety and efficacy of Prelivia — from pre-clinical studies through a 412-patient prospective RCT.

HAPI reduction
87%
Reduction in hospital-acquired pressure injuries in pilot cohort (n=412), Stage II+ — prospective RCT across 3 Magnet-designated hospital systems.
Detection sensitivity at 18hr
91%
True positive rate for tissue damage detection — enabling timely intervention before irreversible sub-surface injury forms or progresses.
Health system ROI
3.28×
Cost savings vs. treatment spend per patient. <4-month payback period and 3.28× Year 1 ROI for a 300-bed hospital deployment.
Tissue oxygenation increase
+28%
Increase in tissue oxygenation (spO₂) in treated patients vs. control. 80% less ischemic injury in pre-clinical studies.

Pre-clinical & clinical validation

Animal & human studies completed. 68 patients across ICU, Acute & LTAC settings. Published in Annals of Biomedical Engineering and Journal of Applied Physiology. 28% increase in tissue oxygenation. 80% reduction in tissue damage.

Prospective RCT — 412 patients

Randomized controlled trial across 3 Magnet-designated hospital systems. 87% HAPI reduction, Stage II+. 91% sensitivity at 18 hours. Zero pressure injuries in treated patients across all completed trial arms. 100% patient acceptance.

5 peer-reviewed publications

Core science peer-reviewed and replicated. RCT submitted to WOUND journal — peer review in progress. IRB approved. NCT registered.

RCT study design
DesignProspective RCT, 3 Magnet hospitals
PopulationICU + Med/Surg, Braden ≤18, n=412
Primary endpointHAPI incidence rate
Nurses trained250 across participating sites
PublicationSubmitted to WOUND — under peer review
Clinical partners
Alberta Health ServicesCleveland ClinicAtrium Health Wake Forest BaptistProvidence Health Care
Regulatory clearances
FDA 510(k)ISO CertifiedHealth Canada Q3 2024CE Mark Q2 2027
Hospital Economics
The business case is undeniable

Per 300-bed hospital deployment — first-year analysis

Annual investment
Daily lead usage — PW beds × days$429,800
Stimulator units purchased (10)$20,000
Total Year 1 Prelivia cost$449,800
Annual benefit
Payer reimbursement + nursing time savings$565,546
CMS penalty avoidance$320,000
Litigation risk reduction$240,000
Total Year 1 savings$1,475,545
<4mo
Payback period · 10-unit acute care hospital deployment
3.28×
Year 1 ROI · invest $449.8K, save $1.475M
$73M ARR
projected 2031 revenue · 97% consumable
$4M
Avg SNF pressure ulcer lawsuit settlement

Speak with our clinical team

Full clinical dossier, peer-to-peer investigator discussions, or facility evaluation support.

Contact medical affairs
Our Differentiators

No one does what we do

Competition is fragmented, reactive, and single-point. NeuroKinetic is the only end-to-end AI platform for pressure injury prevention and management.

Prevention, not treatment

Prelivia stops injuries from forming. Every competitor — wound dressings, alternating pressure mats, turning protocols — treats symptoms after the fact.

Category-defining

Staff-independent efficacy

Electrical stimulation works regardless of staffing ratios or nurse compliance. This is the critical advantage in understaffed SNFs and hospitals.

Structural advantage

Portability across all care settings

Prelivia works in acute care hospitals, SNFs, long-term care, and home health — a single platform that follows the patient across the entire care continuum.

No competitor match

FDA-cleared & IP-protected

FDA 510(k) cleared and ISO certified. 8 patents issued, 2 pending — 15+ years of foundational electrical stimulation IP. Commercially deployable today in the US and Canada.

De-risked
SolutionPrevents InjuryAdaptiveNo Staff RelianceRecurring RevenueSNF-Ready
Prelivia™ (NK)✓✓✓✓✓
Alternating pressure mat~——~~
Manual turning protocols~———✓
Wound dressings (reactive)———✓✓
Vibration/offloading devices~—~—~

See the full clinical evidence

87% HAPI reduction. 3.28× ROI. 5 peer-reviewed publications. The data backs every claim.

Team

Founders built to win

Clinical depth + commercial execution + technology leadership — the three capabilities that matter most in medtech commercialization.

Liz Haar
Liz Haar
Co-Founder & CEO
35+ years in the insurance industry, over half that time as President/CEO of holding companies with diverse companies and lines of business, including healthcare companies and companies delivering services to the healthcare industry. Led the creation, market entry, and growth strategy for several startups, including medtech startups.
Jack Topdjian
Jack Topdjian
Co-Founder & Strategy Officer
Board Member, Venture Operator, Investor and Advisor to health and technology companies. Prior partner at McKinsey, PwC, Booz and Deloitte. With over 30 years of experience in entrepreneurship, advisory and investment services, Jack is recognized as one of the foremost global healthcare industry experts. He is the founder of Healthcare Equity Angels and a healthcare life sciences venture partner of Smartgate VC / Herohouse AI incubator.
Rahul Samant
Rahul Samant
Product Officer
Lead inventor of Prelivia’s core electrical stimulation technology. 15+ years in biomedical engineering research. Pioneered the pre-clinical and clinical validation program underlying NeuroKinetic’s IP portfolio. Author of 5 peer-reviewed publications on electrical stimulation for tissue preservation.
Bojana Turic
Bojana Turic, MD
Clinical & Regulatory Officer
Former Chief Scientific Officer and VP Regulatory Affairs at Rehabtronics. Extensive experience leading regulatory, clinical, and commercialization strategies across medical device, biotechnology, and neurorehabilitation sectors in FDA, Health Canada, and European markets.
RJ McNaughton
RJ McNaughton
Chief Commercial Officer
An award-winning executive leader with extensive experience in strategic planning and team leadership. RJ has led some of the largest and most successful healthcare companies in the world to record sales and profits. He has also helped numerous startup medical companies achieve funding and success in the US.
Chris Hanna
Chris Hanna
Fractional COO
Chris Hanna is the founder and CEO of Walnut Hill Medical, a medical device professional services firm focused on health policy, reimbursement, and commercialization. With 20+ years of commercial and health policy leadership, he has taken multiple Class II and III neurostimulation devices to market. He was a founder and principal commercial leader at Nuvectra Medical, a spinal cord stimulation company, and served as COO of Spark Biomedical.
David G. Armstrong
David G. Armstrong, DPM, MD, PhD
Clinical Board Advisor
Distinguished Professor of Surgery at USC and internationally recognized leader in diabetic foot care, wound healing, and limb preservation. Founder of SALSA and the American Limb Preservation Society, with 770+ peer-reviewed publications and pioneering work in wound care, medical devices, and amputation prevention.
Calie Santana
Calie Santana, MD
Clinical Board Advisor
Physician executive with 18+ years of experience in clinical care, population health, and healthcare innovation. Senior Medical Director for Innovation at Evernorth Health Services and former Chief Medical Officer at Westmed Medical Group, with expertise in AI-enabled healthcare, predictive analytics, value-based care, and improving patient outcomes.
📋 Scientific & Clinical Advisory Board in formation — 3 wound care physicians + 1 former FDA reviewer

Work with us

We’re building a category-defining company. Reach out to discuss clinical collaborations, commercial partnerships, or career opportunities.

Get in touch
Partners

Trusted by leading health systems

Paid pilots, strategic industry relationships, and regulatory clearances across three jurisdictions.

Clinical partners
Cleveland Clinic
Prospective RCT design, clinical efficiency measurement, and care cost analysis
Atrium Health Wake Forest Baptist
RCT participant site — workflow integration study and quality improvement program
Alberta Health Services
Pre-clinical and early clinical validation program
Providence Health Care
Paid 90-day QI pilot — quality improvement program and real-world evidence generation
Industry partners
Medtronic
Strategic industry partnership
Philips
Strategic industry partnership
SWIFT Medical
Wound imaging & documentation integration
NPWT & NALTH
Advisory panels — wound care and long-term hospital leadership
Regulatory clearances
FDA 510(k)
US — Class II. Commercially active.
ISO Certified
International quality management.
Health Canada
Canada — cleared Q3 2024.
CE Mark
EU — targeted Q2 2027.
Commercial traction

US pilots

RCT — 3 Magnet hospitals
Cleveland Clinic
Atrium Health

Paid pilots

Providence 90-day QI
Workflow integration
Real-world evidence

Commercial

US launch active
Canada deployments
250 nurses trained

Interested in partnering?

Whether you’re a health system, device company, distributor, or research institution — we’d like to hear from you.

Contact us
News & Insights

Latest from NeuroKinetic Medical

Clinical insights, research updates, and perspectives from our team.

Clinical Insight June 24, 2026 By Bojana Turic, MD

Beyond Pressure: Understanding the Biology of Pressure Injury Formation

Pressure injuries begin long before the skin breaks down.

When we think about pressure injuries, visible skin damage often comes to mind. In reality, the biological processes leading to tissue injury begin much earlier—and often beneath the skin surface. Understanding what happens before an injury becomes visible is essential for improving prevention strategies.

The Hidden Process: Tissue Ischemia

When soft tissue is compressed between a bony prominence and an external surface for a prolonged period, blood vessels become compressed. As blood flow decreases, tissues receive less oxygen and fewer nutrients while metabolic waste products begin to accumulate.

This condition, known as tissue ischemia, is the first step in pressure injury formation.

Initially, patients may show no visible signs of damage, yet important cellular changes are already occurring. As ischemia persists, cellular energy production declines, inflammation increases, and tissue viability begins to deteriorate. By the time skin changes become visible, significant damage may already have occurred beneath the surface.

Why Oxygen Matters

Healthy tissue depends on a continuous supply of oxygen. Reduced tissue oxygenation impairs normal cellular function by decreasing energy production, slowing tissue repair, and disrupting the removal of metabolic waste. Over time, prolonged hypoxia activates inflammatory pathways and increases the risk of irreversible tissue damage.

Maintaining adequate tissue oxygenation is therefore fundamental to preserving tissue health during periods of immobility.

Muscle is more vulnerable than skin. In fact, muscle tissue is often affected first because it has higher metabolic demands and requires more oxygen than skin. As a result, muscle is considerably more sensitive to prolonged ischemia. This explains why patients may develop significant deep tissue injury while the overlying skin initially appears normal.

Understanding this concept is essential because visual skin assessment alone may underestimate the true extent of tissue injury.

Why Repositioning Alone May Not Always Be Enough

Regular repositioning remains the cornerstone of pressure injury prevention and should continue to be part of standard clinical practice.

However, repositioning primarily relieves external pressure. It does not actively improve tissue perfusion during the long periods patients remain immobile between turns.

For critically ill patients, individuals with spinal cord injuries, residents of long-term care facilities, and others with limited mobility, maintaining healthy tissue physiology may require more than simply changing body position.

The Missing Piece: Movement

One question often asked is: If pressure causes tissue damage, why don’t healthy people develop pressure injuries after sitting at a desk all day in front of computers?

Healthy individuals constantly make small, unconscious movements — shifting weight, adjusting posture, fidgeting. Together, these create a continuous cycle of pressure relief and tissue reperfusion that protects against injury.

Patients confined to a bed or wheelchair lose this mechanism entirely. Pressure remains concentrated over vulnerable tissues, blood flow decreases, and tissue becomes increasingly susceptible to ischemic injury.

In many ways, pressure injuries are not simply the result of pressure — they are the consequence of prolonged, unrelieved pressure combined with the absence of movement.

Every muscle contraction acts as a physiological pump, promoting circulation, venous return, and oxygen delivery to surrounding tissues. When patients become immobile, this mechanism is lost — and tissue perfusion gradually declines.

Prevention is shifting as a result: from pressure redistribution alone, toward preserving tissue health throughout periods of immobility.

Looking Ahead

As pressure injury science advances, prevention is shifting from a reactive, observation-based model to a proactive, physiology-based one. Emerging approaches focus not just on relieving external pressure, but on actively maintaining tissue perfusion and oxygenation during the prolonged periods patients remain immobile between repositioning. Electrical stimulation, smart surface technologies, and AI-driven risk stratification are among the modalities gaining clinical attention — each targeting the underlying biology rather than its visible consequences.

Clinical Insight May 29, 2025 By Bojana Turic, MD

Pressure Ulcers: Between Clinical Reality and Human Experience

Pressure ulcers represent a significant challenge in modern healthcare, particularly among immobile and elderly patients. Despite advances in medical technology and preventive protocols, they remain associated with prolonged hospitalization, increased healthcare costs, and reduced quality of life.

Introduction

While clinical guidelines emphasize prevention and structured care, real-life cases often reveal gaps between theoretical knowledge and everyday practice — especially in home care settings.

Clinical Background

Pressure ulcers develop because of prolonged pressure on soft tissues, most commonly over bony prominences such as the sacrum, heels, hips, and elbows. Prolonged pressure leads to impaired blood circulation, tissue ischemia, and eventual necrosis.

Risk factors include:

  • Reduced mobility or immobility
  • Advanced age
  • Poor nutritional status
  • Incontinence and skin moisture
  • Neurological impairment

Clinical classification ranges from early-stage skin redness to deep tissue damage involving muscles and bones. Early recognition is critical, as progression can be rapid and complications severe.

Case Insight: The Gap Between Care and Outcome

A practical example illustrates this issue clearly: An elderly patient, following a stroke, remained bedridden for several months under family care. Despite genuine effort and dedication, a pressure ulcer developed in the sacral region. The delay in detection was primarily due to insufficient repositioning and limited awareness of early warning signs. By the time professional care was introduced, the wound had already progressed to an advanced stage, requiring intensive treatment.

Management Approach

Effective management of pressure ulcers requires more than local wound care. It involves a comprehensive and coordinated strategy:

  • Local treatment
  • Pressure redistribution
  • Systemic support
  • Continuous monitoring

Evidence from clinical practice shows that combined approaches, supported by advanced wound care technologies and used alongside standard care, lead to better outcomes compared to conservative treatment alone.

The Role of Healthcare Teams

Modern treatment emphasizes the importance of a multidisciplinary approach, involving physicians, nurses, and caregivers. Key elements include:

  • Standardized risk assessment tools (e.g., Braden scale)
  • Clearly defined care protocols
  • Regular evaluation and documentation
  • Education of both healthcare staff and family members

Studies show that consistent application of these protocols can significantly reduce the incidence of pressure ulcers in clinical settings.

Beyond Medicine: The Human Factor

Although pressure ulcers are often discussed in clinical terms, their impact extends far beyond physical health. Patients frequently experience pain and discomfort, emotional distress, and loss of dignity and independence.

Continuous support, communication, and empathy play a crucial role in restoring a patient’s sense of self-worth. Healing is not purely physical.

Prevention as the Primary Strategy

Prevention remains the most effective approach to managing pressure ulcers. Key preventive measures include:

  • Early risk assessment
  • Regular repositioning
  • Skin inspection
  • Maintaining hygiene and dryness
  • Patient and caregiver education

Clinical data consistently demonstrate that institutions applying structured prevention protocols achieve significantly better outcomes, including reduced incidence and improved healing rates.

Conclusion

Pressure ulcers remain a complex medical and social issue, requiring both clinical expertise and human-centered care. Bridging the gap between professional knowledge and everyday caregiving is essential — particularly in home environments where many cases originate.

Timely intervention, education, and a multidisciplinary approach not only improve clinical outcomes but also preserve patient dignity and quality of life.

Contact Our Team